Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 2066 - 2073 |
| Number of pages | 8 |
| Journal | The Analyst |
| Volume | 140 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2015 |
Cite this
}
Spectropathology for the next generation: quo vadis? / Byrne, Hugh J; Baranska, Malgorzata; Puppels, Gerwin J; Stone, Nick; Wood, Bayden Robert; Gough, Kathleen M; Lasch, Peter; Heraud, Philip Robert; Sule-Suso, Josep; Sockalingum, Ganesh D.
In: The Analyst, Vol. 140, No. 7, 2015, p. 2066 - 2073.Research output: Contribution to journal › Editorial › Research › peer-review
TY - JOUR
T1 - Spectropathology for the next generation: quo vadis?
AU - Byrne, Hugh J
AU - Baranska, Malgorzata
AU - Puppels, Gerwin J
AU - Stone, Nick
AU - Wood, Bayden Robert
AU - Gough, Kathleen M
AU - Lasch, Peter
AU - Heraud, Philip Robert
AU - Sule-Suso, Josep
AU - Sockalingum, Ganesh D
PY - 2015
Y1 - 2015
N2 - Although the potential of vibrational spectroscopy for biomedical applications has been well demonstrated, translation into clinical practice has been relatively slow. This Editorial assesses the challenges facing the field and the potential way forward. While many technological challenges have been addressed to date, considerable effort is still required to gain acceptance of the techniques among the medical community, standardise protocols, extend to a clinically relevant scale, and ultimately assess the health economics underlying clinical deployment. National and international research networks can contribute much to technology development and standardisation. Ultimately, large-scale funding is required to engage in clinical trials and instrument development.
AB - Although the potential of vibrational spectroscopy for biomedical applications has been well demonstrated, translation into clinical practice has been relatively slow. This Editorial assesses the challenges facing the field and the potential way forward. While many technological challenges have been addressed to date, considerable effort is still required to gain acceptance of the techniques among the medical community, standardise protocols, extend to a clinically relevant scale, and ultimately assess the health economics underlying clinical deployment. National and international research networks can contribute much to technology development and standardisation. Ultimately, large-scale funding is required to engage in clinical trials and instrument development.
UR - http://pubs.rsc.org.ezproxy.lib.monash.edu.au/en/content/articlepdf/2015/an/c4an02036g
U2 - 10.1039/c4an02036g
DO - 10.1039/c4an02036g
M3 - Editorial
VL - 140
SP - 2066
EP - 2073
JO - The Analyst
JF - The Analyst
SN - 0003-2654
IS - 7
ER -